EP Patent

EP3339292A1 — Cocrystals of apremilast

Assigned to Zaklady Farmaceutyczne Polpharma SA · Expires 2018-06-27 · 8y expired

What this patent protects

The invention relates to cocrystals of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide (Apremilast) with caffeine (APM-CAF) and 4-hydroxybenzoic acid (APM-4HB). It also refers to pharmaceutical compositions and dos…

USPTO Abstract

The invention relates to cocrystals of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide (Apremilast) with caffeine (APM-CAF) and 4-hydroxybenzoic acid (APM-4HB). It also refers to pharmaceutical compositions and dosage forms comprising said cocrystals. The invention also concerns said pharmaceutical compositions or dosage forms for use in a method of treating a disease or disorder defined in the claims. Finally, the invention pertains to the use of said cocrystals for the preparation of pharmaceutical compositions and dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP3339292A1
Jurisdiction
EP
Classification
—
Expires
2018-06-27
Drug substance claim
No
Drug product claim
No
Assignee
Zaklady Farmaceutyczne Polpharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.